FDA Updates Testosterone Labeling for Blood Pressure and Cardiovascular Risks
The US Food and Drug Administration (FDA) recently issued class-wide labeling changes for testosterone products, recommending that labels include a warning about increased blood pressure and remove language related to elevated risk of adverse cardiovascular outcomes.
The US Food and Drug Administration (FDA) recently issued class-wide labeling changes for testosterone products, recommending that labels include a warning about increased blood pressure and remove language related to elevated risk of adverse cardiovascular outcomes.
